CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 19 enrolled
Drug / intervention
LD-Aminopterin oral capsule +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03431974
NCT03431974Phase 2Completed
CompareCT.gov

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial to Establish the Efficacy and Safety of Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis

Syntrix Biosystems, Inc.·interventional·Posted Feb 13, 2018·Updated Apr 14, 2023

In Brief

A Phase 2 clinical trial evaluating LD-Aminopterin oral capsule and Placebo oral capsule for Psoriasis. Completed, enrolled 19 participants across 3 sites.

Detailed Summary

This study evaluates the treatment of psoriasis with aminopterin. Participants will be treated for 14 weeks with either aminopterin or placebo followed. The participants will not know if they are being treated with aminopterin or placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesUnited States
CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID)

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedFeb 13, 2018
Enrollment StartNov 1, 2018
Primary CompletionJan 11, 2021
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 8.4 years ago

Interventions

LD-Aminopterin oral capsuledrug

anti-folate treatment

Placebo oral capsuledrug

Microcrystalline filled capsule to mimic capsule containing aminopterin tablets